- Bruker Corp‘s second-quarter revenue met expectations at $800.7 million, slightly above the estimate of $799.3 million.
- Adjusted EPS (Earnings Per Share) for the quarter was 52 cents, marginally beating the estimate of 51 cents.
- Bruker has updated its FY 2024 non-GAAP EPS guidance to a range of $2.59 to $2.64, up from FY 2023’s non-GAAP EPS of $2.58.
- The company’s strong organic growth is fueled by its innovative products and favorable market trends in the post-genomic era.
- Analyst recommendations for Bruker include 6 buys, 2 holds, and 2 sells.
A look at Bruker Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma’s Smart Scores, Bruker Corp is looking towards a promising long-term future. With a solid growth score of 4, the company is expected to expand and develop in the upcoming years. This indicates that Bruker Corp is positioned well for progress and enhancement in its market segments.
Although some areas such as value, dividend, resilience, and momentum have received slightly lower scores, the overall outlook remains positive for Bruker Corp. The company’s focus on designing, manufacturing, and marketing life science systems, combined with its innovative technology platforms, positions it well for future success and sustainability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
